Trevi Therapeutics, Inc. (TRVI): Price and Financial Metrics

Trevi Therapeutics, Inc. (TRVI): $2.65

0.12 (-4.33%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

TRVI Price/Volume Stats

Current price $2.65 52-week high $4.00
Prev. close $2.77 52-week low $0.97
Day low $2.50 Volume 286,100
Day high $2.78 Avg. volume 245,467
50-day MA $2.75 Dividend yield N/A
200-day MA $2.15 Market Cap 186.65M

TRVI Stock Price Chart Interactive Chart >


Trevi Therapeutics, Inc. (TRVI) Company Bio


Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT.


TRVI Latest News Stream


Event/Time News Detail
Loading, please wait...

TRVI Latest Social Stream


Loading social stream, please wait...

View Full TRVI Social Stream

Latest TRVI News From Around the Web

Below are the latest news stories about TREVI THERAPEUTICS INC that investors may wish to consider to help them evaluate TRVI as an investment opportunity.

Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for patients with chronic cough in idiopathic pulmonary fibrosis (IPF), refractory chronic cough (RCC), and prurigo nodularis, today announced the initiation of its Phase 2b CORAL clinical trial evaluating three doses of Haduvio against placebo in approximately 160 IPF patients with chronic cough. This Phase 2b trial builds on the positive resul

Yahoo | December 5, 2023

Down -38.07% in 4 Weeks, Here's Why You Should You Buy the Dip in Trevi Therapeutics, Inc. (TRVI)

The heavy selling pressure might have exhausted for Trevi Therapeutics, Inc. (TRVI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Yahoo | November 30, 2023

Trevi Therapeutics, Inc. (TRVI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Trevi Therapeutics, Inc. (TRVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Yahoo | November 14, 2023

After Plunging -28.72% in 4 Weeks, Here's Why the Trend Might Reverse for Trevi Therapeutics, Inc. (TRVI)

The heavy selling pressure might have exhausted for Trevi Therapeutics, Inc. (TRVI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Yahoo | November 14, 2023

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q3 2023 Earnings Call Transcript

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q3 2023 Earnings Call Transcript November 12, 2023 Operator: Good afternoon and welcome to the Trevi Therapeutics Q3 2023 Earnings Conference Call. At this time all participants will be in a listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this […]

Yahoo | November 12, 2023

Read More 'TRVI' Stories Here

TRVI Price Returns

1-mo -4.33%
3-mo -23.41%
6-mo 105.43%
1-year 7.72%
3-year 29.90%
5-year -72.11%
YTD 97.76%
2023 -30.57%
2022 146.74%
2021 -67.68%
2020 -35.47%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!